Skip to main content



) --




) hit a new 52-week high Wednesday as it is currently trading at $45.04, above its previous 52-week high of $45 with 619,979 shares traded as of 2:49 p.m. ET. Average volume has been 641,300 shares over the past 30 days.

Cepheid has a market cap of $2.83 billion and is part of the


sector and


industry. Shares are up 26.5% year to date as of the close of trading on Tuesday.

TheStreet Recommends

Cepheid, a molecular diagnostics company, engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

TheStreet Ratings rates Cepheid as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and disappointing return on equity. You can view the full

Cepheid Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center